LEO PAVLIV
Pharmacy in Cary, NC
License number
New Jersey 28RI01786700
Issued Date
Jan 8, 1984
Expiration Date
Apr 30, 2007
Category
Pharmacy
Type
Pharmacist
Address
Address
Cary, NC
Professional information
Pharmaceutical Composition Of 2-(4-Isobutylphenyl) Propionic Acid
US Patent:
6727286, Apr 27, 2004
Filed:
Nov 2, 2001
Appl. No.:
09/985246
Inventors:
Leo Pavliv - Morrisville NC
Assignee:
Cumberland Pharmaceuticals Inc. - Nashville TX
International Classification:
A61K 31195
US Classification:
514565, 514568, 514 57
Abstract:
The present invention provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, as well as a method of making the same. The present invention also provides a method of treating a condition chosen from pain, inflammation, fever, and/or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1.
Fatty Acid Formulations And Oral Delivery Of Proteins And Peptides, And Uses Thereof
US Patent:
8563685, Oct 22, 2013
Filed:
Oct 20, 2009
Appl. No.:
12/581953
Inventors:
Balasingam Radhakrishnan - Chapel Hill NC, US
Diti Aggarwal - Raleigh NC, US
Michelle Ferro - Raleigh NC, US
Kenneth D. James - Mebane NC, US
Navdeep B. Malkar - Cary NC, US
Mark A. Miller - Raleigh NC, US
Leo Pavliv - Morrisville NC, US
Karen Polowy - Raleigh NC, US
Monica Puskas - Spring Hope NC, US
Nnochiri N. Ekwuribe - Cary NC, US
Diti Aggarwal - Raleigh NC, US
Michelle Ferro - Raleigh NC, US
Kenneth D. James - Mebane NC, US
Navdeep B. Malkar - Cary NC, US
Mark A. Miller - Raleigh NC, US
Leo Pavliv - Morrisville NC, US
Karen Polowy - Raleigh NC, US
Monica Puskas - Spring Hope NC, US
Nnochiri N. Ekwuribe - Cary NC, US
Assignee:
Biocon Limited
International Classification:
C07K 14/62
US Classification:
530303, 530345, 514 59, 514 69
Abstract:
Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0. 1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0. 1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.
Pharmaceutical Composition Of 2-(4-Isobutylphenyl) Propionic Acid
US Patent:
2004013, Jul 8, 2004
Filed:
Dec 19, 2003
Appl. No.:
10/739050
Inventors:
Leo Pavliv - Cary NC, US
International Classification:
A61K031/198
US Classification:
514/565000, 514/570000
Abstract:
The present invention provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, as well as a method of making the same. The present invention also provides a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the solution has a pH of less than about 7.8, as well as a method of making the same. The present invention also provides a method of treating a condition chosen from pain, inflammation, fever, and/or other conditions alleviated by ibuprofen comprising administering a pharmaceutical composition comprising an aqueous solution of arginine and ibuprofen, wherein the molar ratio of arginine to ibuprofen is less than 1:1, and wherein the molar ratio of arginine to ibuprofen is selected to achieve a pH of less than about 7.8.
Fatty Acid Formulations For Oral Delivery Of Proteins And Peptides, And Uses Thereof
US Patent:
7605123, Oct 20, 2009
Filed:
Jul 19, 2005
Appl. No.:
11/184528
Inventors:
Balasingam Radhakrishnan - Chapel Hill NC, US
Diti Aggarwal - Raleigh NC, US
Michelle Ferro - Raleigh NC, US
Kenneth D. James - Mebane NC, US
Navdeep B. Malkar - Cary NC, US
Mark A. Miller - Raleigh NC, US
Leo Pavliv - Morrisville NC, US
Karen Polowy - Raleigh NC, US
Monica Puskas - Spring Hope NC, US
Nnochiri N. Ekwuribe - Cary NC, US
Diti Aggarwal - Raleigh NC, US
Michelle Ferro - Raleigh NC, US
Kenneth D. James - Mebane NC, US
Navdeep B. Malkar - Cary NC, US
Mark A. Miller - Raleigh NC, US
Leo Pavliv - Morrisville NC, US
Karen Polowy - Raleigh NC, US
Monica Puskas - Spring Hope NC, US
Nnochiri N. Ekwuribe - Cary NC, US
Assignee:
Biocon Ltd.
International Classification:
A61K 38/28
US Classification:
514 3, 514 2, 514 4, 530303, 530345
Abstract:
Fatty acid compositions for administration of of pharmaceutical agents, such as proteins and peptides, protein and peptide conjugates, and/or cation-polypeptide conjugate complexes. In particular, the invention provides a solid pharmaceutical composition formulated for oral administration by ingestion, having from about 0. 1 to about 75% w/w fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent. Further, the invention provides a liquid pharmaceutical composition formulated for oral administration by ingestion, comprising: from about 0. 1 to about 10% w/v fatty acid component, where the fatty acid component comprises saturated or unsaturated C4, C5, C6, C7, C8, C9, C10, C11, or C12 fatty acids and/or salts of such fatty acids; and a therapeutic agent.
Lyophilized Viral Formulations
US Patent:
2012014, Jun 7, 2012
Filed:
Dec 2, 2011
Appl. No.:
13/309901
Inventors:
Matthew C. Coffey - Calgary, CA
Sarah Serl - Calgary, CA
Leo Pavliv - Cary NC, US
Sarah Serl - Calgary, CA
Leo Pavliv - Cary NC, US
Assignee:
ONCOLYTICS BIOTECH INC. - Calgary
International Classification:
A61K 35/76, A61P 31/14, A61P 37/04, A61K 39/12, A61K 39/15
US Classification:
4242151, 4242041, 424 936
Abstract:
Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
Liquid Viral Formulations
US Patent:
2012014, Jun 7, 2012
Filed:
Dec 2, 2011
Appl. No.:
13/309966
Inventors:
Matthew C. Coffey - Calgary, CA
Sarah Serl - Calgary, CA
Leo Pavliv - Cary NC, US
Sarah Serl - Calgary, CA
Leo Pavliv - Cary NC, US
Assignee:
ONCOLYTICS BIOTECH INC. - Calgary
International Classification:
A61K 35/76, A61P 35/00
US Classification:
424 932, 424 936
Abstract:
Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
Acetycysteine Compositions And Methods Of Use Thereof
US Patent:
2012002, Jan 26, 2012
Filed:
Jul 21, 2011
Appl. No.:
13/188152
Inventors:
Leo PAVLIV - Cary NC, US
Assignee:
Cumberland Pharmaceuticals, Inc. - Nashville TN
International Classification:
A61K 31/197, A61P 1/08, A61P 1/16, A61P 11/02, A61P 17/04, A61P 17/00, A61P 9/00, A61P 11/04
US Classification:
514562
Abstract:
A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed.
Injectable Ibuprofen Formulation
US Patent:
2013024, Sep 19, 2013
Filed:
Mar 16, 2012
Appl. No.:
13/422738
Inventors:
Leo Pavliv - Cary NC, US
Andrew Vila - Nashville TN, US
Andrew Vila - Nashville TN, US
Assignee:
Cumberland Pharmaceuticals Inc. - Nashville TN
International Classification:
A61K 31/19, A61P 9/00, A61J 1/10, A61P 29/00
US Classification:
604408, 514570
Abstract:
The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.
Treating Critically Ill Patients With Intravenous Ibuprofen
US Patent:
2011002, Feb 3, 2011
Filed:
Jul 6, 2010
Appl. No.:
12/830991
Inventors:
Leo PAVLIV - Cary NC, US
Amy Dix Rock - Nashville TN, US
Amy Dix Rock - Nashville TN, US
Assignee:
Cumberland Pharmaceuticals Inc. - Nashville TN
International Classification:
A61K 31/192, A61P 29/00
US Classification:
514570
Abstract:
Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
Injectable Ibuprofen Formulation
US Patent:
2013024, Sep 19, 2013
Filed:
Mar 16, 2012
Appl. No.:
13/422761
Inventors:
Leo Pavliv - Cary NC, US
Andrew Vila - Nashville TN, US
Andrew Vila - Nashville TN, US
Assignee:
Cumberland Pharmaceuticals Inc. - Nashville TN
International Classification:
A61K 31/19, A61P 29/00, A61J 1/10, A61J 1/00, B65D 30/02, A61K 31/195, A61P 9/00
US Classification:
514561, 514570, 206438, 604408
Abstract:
The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.